Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Non-Small Cell Lung Cancer.

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Metastatic Breast Cancer.

The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National ...

High levels of immune infiltrates are strongly prognostic for favorable outcomes independently of nodal status in ...

INR:0738. play microgaming slots R&D Daily: AstraZeneca's PD-L1 inhibitor receives priority review, reducing the number of treatments by half Phase 3 clini ...

INR:9702. 247 casino Novartis' MET inhibitor receives breakthrough therapy designation, while Roche's PD-L1 inhibitor expands patient population Shanghai Pharmaceutica ...

INR:6695. aus world cup squad CStone Pharmaceuticals initiates clinical trial of PD-L1 inhibitor combined with FGFR4 inhibitor Microhotspot丨A ticket scalper ...